

Press release 2015-11-23

## **The US Patent and Trademark Office issues a Notice of allowance for new Foxy-5 patent**

WntResearch AB today announces that the United States Patent and Trademark Office has issued a Notice of Allowance for a new Foxy-5 patent, covering treatment of prostate cancer.

CEO Nils Brünner comments: *"It is very satisfactory that we will now have a US-patent covering our lead compound Foxy-5 for the treatment of prostate cancer. This patent expands our patent portfolio in a field where there is a very high medical need for new drugs. We do see Foxy-5 as a drug filling a gap in the treatment of prostate cancer, where all too many men will experience metastatic disease with subsequent death. In our newly finalized clinical phase 1 study we obtained the first indications of anti-cancer effects of Foxy-5 in patients with prostate cancer. It is especially gratifying to have this patent in place since it will not only cover treatment of prostate cancer but it will also provide WntResearch with prolonged patent life for Foxy-5."*

### **For additional information please contact:**

Nils Brünner, CEO

E-mail: [nbr@wntresearch.com](mailto:nbr@wntresearch.com)

Telephone: + 45 2614 4708

### **About WntResearch**

WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer.

WntResearch has one drug candidate in clinical phase 1 – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.